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Background. Studies have demonstrated that self-testing for human immunodeﬁciency virus (HIV) is highly
acceptable among individuals and could allow cost savings, compared with provider-delivered HIV testing and coun-
seling (PHTC), although the longer-term population-level effects are uncertain. We evaluated the cost-effectiveness
of introducing self-testing in 2015 over a 20-year time frame in a country such as Zimbabwe.
Methods. The HIV synthesis model was used. Two scenarios were considered. In the reference scenario, self-
testing is not available, and the rate of ﬁrst-time and repeat PHTC is assumed to increase from 2015 onward, in line
with past trends. In the intervention scenario, self-testing is introduced at a unit cost of $3.
Results. We predict that the introduction of self-testing would lead to modest savings in healthcare costs of $75
million, while averting around 7000 disability-adjusted life-years over 20 years. Findings were robust to most vari-
ations in assumptions; however, higher cost of self-testing, lower linkage to care for people whose diagnosis is a con-
sequence of a positive self-test result, and lower threshold for antiretroviral therapy eligibility criteria could lead to
situations in which self-testing is not cost-effective.
Conclusions. This analysis suggests that introducing self-testing offers some health beneﬁts and may well save costs.
Keywords. HIV; self-testing; cost-effectiveness; mathematical modeling; diagnostic.
In recent years, the scale up of antiretroviral therapy
(ART) in low-income countries has been dramatic,
helping transform human immunodeﬁciency virus
(HIV) infection from a terminal illness to a chronic
condition. Nevertheless, more than 50% of people living
with HIV remain unaware of their HIV status [1]. They
are therefore unable to beneﬁt from HIV care and ART
and to take action to reduce their risks of transmitting
HIV. There are many reasons some people decide not
to actively seek an HIV test, including fear of stigma
discrimination, perceived lack of conﬁdentiality, incon-
venience and costs associated with accessing testing [2].
Some of these barriers relate particularly to current pro-
vider-based models of testing (eg, standard voluntary
counseling and testing [VCT] and provider-initiated
testing and counseling) and may be at least partially
overcome through use of self-testing for HIV [3] if
this were available as an alternative.
Self-testing involves individuals collecting and testing
their own samples (typically saliva) without the involve-
ment of a healthcare professional. Possible advantages
of self-testing over more-standard provider-delivered
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HIV testing and counseling (PHTC) include greater conve-
nience, conﬁdentiality, and empowerment for users. Self-testing
has potential to reach people who, for a variety of reasons, have
chosen not to have an HIV test, using the PHTC option. Its
availability may also lead to an increase in the frequency at
which individuals choose to test for HIV.
A number of self-test kits remain under development by man-
ufacturers. The costs of the kits themselves are likely to be slightly
higher than for equivalent kits used in clinical settings, mainly be-
cause of the need for packaging and associated marketing. How-
ever, overall, the cost per test of self-testing is expected to be less
than with PHTC, owing to a lack of healthcare worker involvement
at the time of screening [4].This needs to be balanced against pos-
sible disadvantages of self-testing, including a sensitivity that is
likely to be lower than that of PHTC [5], the need for a conﬁrma-
tory PHTC for a deﬁnitive HIV-positive diagnosis, the potential
for linkage to posttest care to be less likely or less timely, as well as
possible adverse psychological impacts due to receiving a HIV-
positive result without the direct support of a trained counselor.
In 2012, the US Food and Drug Administration (FDA) ap-
proved the OraQuick In-Home HIV Test as the ﬁrst HIV self-
test kit. The kit is sold over the counter in the United States for
$40. In low-income countries, regulated self-test kits are gener-
ally not available. Donors and stakeholders are evaluating
whether investments should be made to support the develop-
ment, promotion, and marketing of self-tests in low-income
countries. Preliminary research conducted in Kenya and Mala-
wi showed that acceptability and uptake is high, that accuracy is
relatively good, and that there are interventions that appear to
be effective in linking self-testers to HIV care [6–10].
Mathematical models offer a framework for evaluating the bal-
ance of the advantages and disadvantages of self-testing. Hence,
they can provide insights into the potential net costs and health
effects of self-testing at a population level over the longer term
and can help determine whether introducing free or subsidized
self-testing would be cost-effective. The aim of this study is to as-
sess the potential cost-effectiveness and examine the main drivers
of introducing self-testing in the general population over 20 years
in a low-income countries such as Zimbabwe.
METHODS
HIV Synthesis Transmission Model
We used an updated version of the HIV Synthesis Transmission
Model, an individual-based stochastic model of HIV transmis-
sion and infection progression and treatment among heterosex-
uals that has been previously described [11–13]. All variables in
the model are updated in 3-month intervals. The model in-
cludes an age structure, and sexual risk behavior is modeled
as the number of short-term partners with whom sex is con-
domless and the presence of a long-term partner with whom
sex is condomless in each period. In any given period, the
probability of an HIV-negative person having condomless sex
with a partner who is HIV-positive depends on the number
of sex partners of the HIV-negative partner and on the preva-
lence of HIV among the sex partners, accounting for patterns of
age mixing. Given exposure to an HIV-positive sex partner, the
probability of transmission depends on the viral load of the
partner (obtained by sampling from the distribution of viral
loads in partnerships formed by HIV-positive people, account-
ing for gender and age), on the estimated risk of transmission at
that viral load, on the presence of a concurrent sexually trans-
mitted infection, and on gender. For people who have become
infected with HIV, the variables modeled include their viral
load and CD4+ T-cell count, whether resistance mutations are
present in their viral population, their risk of AIDS and death,
whether they have tested positive for HIV, whether they are
linked to care, whether they are remaining in care, and whether
they are receiving treatment, if eligible. The model of progres-
sion of HIV and the effect of ART has been shown to provide a
generally close ﬁt to observed data relating to the natural pro-
gression of HIV infection and the effect of ART [12, 14]. So
that observed trends in testing and the proportion of infected in-
dividuals receiving a diagnosis can be mimicked, people within
the model who have not tested positive for HIV and who have
access to HIV testing have an increasing chance over calendar
years to be tested for HIV. In addition, pregnant women can ac-
cess HIV testing through antenatal clinics. Updates to the model
presented here, compared with the version of the model previ-
ously published, include age and gender-speciﬁc rates of ﬁrst-
time and repeat testing, including self-testing, and calibration
to reﬂect HIV prevalence and age-speciﬁc and gender-speciﬁc
levels of testing observed in Zimbabwe (Supplementary Materi-
als) [15]. The model was programmed in SAS software, version
9.3 (SAS Institute, Cary, North Carolina).
Scenarios Modeled
The HIV epidemic in Zimbabwe is simulated until 2015 on the
basis of existing data on HIV prevalence and HIV testing [15].
From 2015, we compare two possible base case scenarios: a ref-
erence scenario, in which self-testing is not introduced and
there is continued reliance on PHTC alone, and the self-testing
scenario, in which self-testing is made available to the general
population aged 15–65 years from 2015 onward. In the refer-
ence scenario, the rates of ﬁrst-time and repeat testing increase
linearly by 0.5% per year (the proportion tested for HIV in the
last year is 39% in 2015, increasing up to 48% in 2035), and the
rates of being linked to care, being retained in pre-ART care,
and initiating ART, if eligible, remain the same as they were be-
fore 2015. One single simulation run was performed up to 2015,
while several hundred runs were simulated for the two scenarios
from 2015 through 2035, with means taken to limit stochastic
effects (the extent of uncertainty due to stochastic effects is
conveyed by providing 95% conﬁdence limits).
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The introduction of self-testing is assumed to have 3 main
effects: (1) halving of the population unwilling to receive an
HIV test ( from 5% to 2.5%), (2) substituting 10% of ﬁrst-
time and 30% of repeat PHTC with self-tests, and (3) increasing
the rate of ﬁrst-time and repeat testing by 20%, owing to the
availability of self-testing. The availability of self-testing is not
assumed to affect PHTC in antenatal care settings. These as-
sumptions are based on limited current evidence but, overall,
are believed to be conservative in estimating the potential ben-
eﬁts of self-testing.
Additional Assumptions
The sensitivity and speciﬁcity of self-testing were assumed to be
92% and 99%, respectively, as observed in the studies leading to
FDA approval of the OraQuick In-Home HIV Test [16]. Vari-
ability across studies has been observed in the sensitivity of the
OraQuick In-Home HIV Test, mainly reﬂecting the models and
approaches used for HIV self-testing and the population of in-
dividuals who tested for HIV. High accuracy (99.2%) has been
found both in studies that offered supervised self-testing [6] and
studies characterized by a lower level of supervision [10, 17, 18].
To our knowledge, only one study reported a lower accuracy
than that identiﬁed in the OraQuick FDA studies [19], and
this was due to the lack of information given on how to interpret
a faint positive result and to the fact that people receiving ART
were self-testing. It is known that ART may decrease the overall
sensitivity of oral ﬂuid-based self-testing [19, 20]. In this anal-
ysis, we assumed that only people who had an unknown HIV
status (and were therefore not receiving ART) could use self-
testing.
PHTC was considered more accurate, with a sensitivity esti-
mated to be 98% [21] and a speciﬁcity of 100% (given conﬁrma-
tory testing, when a person is found to be HIV positive, it is
unlikely that a person receives a diagnosis of HIV infection if
they are not infected).
Once a person receives a positive self-test result, a conﬁrma-
tory PHTC was assumed to be necessary to consider a person as
having a diagnosis of HIV infection, as well as the possibility of
linking that person to care (ie, where they receive an ART-
eligibility assessment) and eventually initiating ART. The proba-
bility of a conﬁrmatory PHTC by 1 year following a positive
self-test result was assumed to be 0.8, based on evidence that,
in the context of supervised self-testing, most people disclose
to their counselor [10]. Once the person receives a diagnosis
(following a positive PHTC result), the probability of being
linked to care was assumed to be 0.6 within 1 year after
diagnosis [22], regardless of whether they initially underwent
self-testing or PHTC. No change in the frequency of condomless
sex among people who tested negative for HIV was assumed,
whereas those who tested positive for HIV reduced the frequency
of condomless sex with casual partners by 17% in the ﬁrst 6
months (and by 9% afterward) and by 13% with long-term
partners, regardless of the type of HIV test. In the context of
VCT, there is evidence that this is the case [23], and in the
base case we assume that this holds for self-testing, although
we are assuming quite a small effect. People were assumed to
be eligible for ART when their CD4+ T-cell count decreased to
below 500 cells/mm3 in the base case, in line with guidelines in
Zimbabwe [24] and from theWHO [25]. Implementation of pre-
vention of mother-to-child-transmission option B+ (ie, provision
of lifelong ART for pregnant and breast-feeding women) was not
taken into account.
Economic Analysis
The two scenarios (the reference scenario and the self-testing
scenario) were compared on the basis of their costs and health
outcomes, which are both discounted to present values at 3%
per annum, from a healthcare perspective [26]. Costs were esti-
mated on the basis of resource use (eg, number of tests and
number of clinic visits) and associated unit costs. The fully load-
ed cost of a PHTC was assumed to be $9 for a negative test result
and $25 for a positive test result or a conﬁrmatory test following
a positive self-test result, so that the average cost was around $10
[27]. The fully loaded cost of self-testing was assumed to be $3
per unit. Health outcomes were summarized in the form of dis-
ability-adjusted life-years (DALYs) averted, which captures
changes in both mortality and morbidity, including the impact
on onward HIV transmission (Supplementary Materials) [28].
Results are presented across a range of cost-effectiveness thresh-
olds (CETs) from $0 (an extreme case, implying a health system
would only be concerned with reducing costs) to $10 000 (a rela-
tively high threshold only likely to be relevant in well-ﬁnanced
health systems with full coverage of interventions offering health
gains at less than this amount).
Costs and health outcomes were rescaled to provide ﬁgures
relevant to the entire adult population (15–65 years old) of
Zimbabwe. Because of the stochastic variation inherent in
the model, a high number of simulations were required, so ﬁg-
ures are presented on a discrete scale, rather than a continuous
scale.
Sensitivity Analyses
The following parameters were varied in univariate sensitivity
analyses: the cost of self-testing, the sensitivity of self-testing,
the probability of PHTC as a direct consequence of a positive
self-test, the probability of being linked to care by 1 year after
a positive PHTC result (whether prompted by a self-testing or
not), and the reduction in the frequency of condomless sex for
those receiving a diagnosis on the basis of a positive self-test
result, eligibility criteria to initiate ART, the magnitude of the
increase in the rates of ﬁrst and repeat testing due to the
introduction of self-testing, and the level of substitution of
self-testing for PHTC. The most determinant parameters of
cost-effectiveness were also varied in multivariate analyses.
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RESULTS
Introduction of self-testing, as assumed in the base case scenar-
io, led in 2035 to a 7% higher proportion tested for HIV in the
past year, compared with the reference scenario (57% vs 50%;
Table 1). The total discounted costs over 20 years for HIV test-
ing and resulting HIV care and ART under the reference sce-
nario base case assumptions is estimated to be almost $3.1
billion (Figure 1). Of this, 40% is attributable to the cost of
antiretroviral drugs, around a quarter to the cost of clinic visits,
and 24% to the cost of PHTC. Over a 20-year period, the self-
testing scenario is predicted to lead to savings of $75 million
(95% conﬁdence interval [CI], $73 million–$77 million), for a
cost reduction of 2.6%, due primarily to lower testing costs.
The introduction of self-testing would also result in health
gains, with approximately 7000 DALYs averted (95% CI, 700–
13 000 DALYs averted; Table 2).
Table 2 summarizes increments in total discounted costs and
total discounted DALYs averted with the self-testing scenario,
compared with the reference scenario, along with the cost-
effectiveness of self-testing, under the base case and alternative
assumptions in sensitivity analyses. This is provided for different
CETs. In general, for any scenario in which DALYs are averted,
the probability that self-testing is cost-effective will increase with
increasing CETs, because at some point the cost of the DALYs
averted becomes affordable. In contrast, for scenarios that lead
to a loss in DALYs, self-testing is less likely to be cost-effective
with increasing CETs because at some point the money saved
from the self-testing scenario is not worth the loss in DALYs.
The results are particularly driven by the cost of self-testing itself.
If the cost of self-testing is the same as that of a negative result of a
PHTC-associated test ($9), it is not cost-effective at a CET of
$10 000 per DALY averted or less because it results in higher
costs ($136 million more than under the reference scenario)
but relatively small health gains. If, however, self-testing were
to cost $4 or less, then the self-testing scenario would be cost-
effective even at a CET of $500, keeping other base case assump-
tions ﬁxed (Figures 3 and 4).
The level of substitution of PHTC with self-testing affects the
results in a slightly counterintuitive way (Figure 2). At all CETs
considered ($1–$1000), the lower cost self-testing is preferred
even when the probability of PHTC following a positive self-
test result (and therefore the chance of receiving a diagnosis)
is low; this is the case even at relatively high CETs, because
even if the probability of PHTC as a direct consequence of
a positive self-test is low and the level of substitution high,
the cost savings outweighs the loss in health. Self-testing is
clearly more likely to be cost-effective as the cost of self-testing
decreases (Figures 3 and 4).
Regarding the levels of increase in the frequencies of under-
going an initial test and a repeat test due to the availability of
self-testing (Figure 4), we found that the greater the levels of
increase, the greater the total cost; however, this is counterbal-
anced by the dramatic cost savings due to the partial substitu-
tion of PHTC with self-testing.
Table 1. Predictions Over Time in the Reference Scenario and the Self-Testing Scenario
Variable 2011 DHS Dataa
Model Estimate
Baseline
Reference Scenario
Self-Testing
Scenario
2015 2025 2035 2025 2035
HIV prevalence, % 15 13 10 7 10 7
Ever tested for HIV, % 50 66 77 79 80 83
Tested for HIV in the past year, % 28 39 48 50 54 57
Received HIV infection diagnosis, % . . . 85 91 93 92 93
HIV-positive patients receiving ART, % . . . 56 66 69 66 69
Model estimates are median values of all simulations.
Abbreviations: ART, antiretroviral therapy; HIV, human immunodeficiency virus.
a Demographic and Health Surveys (DHS) [15].
Figure 1. Total discounted cost over 20 years. Abbreviations: ART,
antiretroviral therapy; CD4, CD4+ T-cell count; CTX, cotrimoxazole; PHTC,
provider-delivered human immunodeﬁciency virus testing and counseling;
RS, reference scenario; ST, self-testing; STS, self-testing scenario; WHO
3/4, treatment of World Health Organization stage 3 and 4 human immu-
nodeﬁciency virus disease [29].
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Table 2. Cost-effectiveness for the Self-Testing Scenario (STS) and Reference Scenario (RS) Under Base Case Assumptions and
Alternative Assumptions and According to Cost-effectiveness Threshold
Variable
Cost-effectiveness Threshold, $ Total Discounted Change
in Costs, × $1 Million,
Compared With RS (95% CI)
Discounted DALYs Averted,
×1000, Compared With RS
(95% CI)0 500 1000 5000 10 000
Base casea STS STS STS STS STS −75 (−77 to −73) 7 (.7–13)
Cost of ST, $9 (base case: $3) RS RS RS RS RS 136 (134–137) 7 (.7–13)
Sensitivity of ST, 0.55 (base case: 0.92) STS STS STS STS RS −81 (−84 to −79) −11 (−22 to −.5)
Probability of PHTC as a direct
consequence of a positive ST, 0.37
(base case: 0.8)
STS STS STS STS STS −87 (−90 to −84) 0.1 (−11 to 11)
Linkage to care following diagnosis for
those who had a ST of 0.4 by 1 y (base
case: 0.6)
STS STS STS RS RS −105 (−112 to −97) −19 (−32 to −6)
ART initiation at CD4 <350 cells/mm3
(base case: CD4 <350 cells/mm3
without introduction of ST)
STS STS STS RS RS −69 (−74 to −64) −21 (−40 to −2)
No reduction in condomless sex following
a positive ST (base case: as PHTC)
STS STS STS STS STS −74 (−77;−70) 19 (6–33)
Increase in rate of first test due to ST (base case: 20%)
2.5% STS STS STS STS STS −82 (−85 to −79) 10 (−.6 to 20)
7.5% STS STS STS STS STS −81 (−85 to −78) 13 (−.6 to 26)
Increase in rate of repeat test due to ST (base case: 20%)
2.5% STS STS STS STS STS −102 (−105 to −99 4 (−6 to 14)
7.5% STS STS STS STS STS −82 (−86 to −78) 13 (−1 to 26)
Substitution (base case: 30% for repeat test, 10% for first test)
5% for repeat test, 2% for first test RS RS STS STS STS 38 (34–41) 39 (20–57)
15% for repeat test, 5% for first test STS STS STS STS STS −12 (−17 to −7) 22 (5–39)
25% for repeat test, 8% for first test STS STS STS STS STS −52 (−57 to −47) 20 (.5–39)
The discounted total cost of the RS over 20 years from 2015 is $3168 million.
Abbreviations: ART, antiretroviral therapy; CD4, CD4+ T-cell count; CI, confidence interval; DALY, disability-adjusted life-year; PHTC, provider-delivered human
immunodeficiency virus testing and counseling; ST, self-testing.
a See the “Scenarios Modeled” subsection in “Methods” section.
Figure 2. Cost-effective scenario under different assumptions of substitution and probability of provider-delivered human immunodeﬁciency virus testing
and counseling (PHTC) as a direct consequence of a positive self-testing (ST). Abbreviations: CET, cost-effectiveness threshold; F, substitution of PHTC with
self-testing during ﬁrst test; R, substitution of PHTC with self-testing during repeat test.
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DISCUSSION
Self-testing holds the promise of expanding the reach of HIV
testing. It may enable some people to test who would not oth-
erwise choose PHTC because of stigma, conﬁdentiality, cost, or
other barriers to access. It may also increase the overall frequen-
cy of testing in the population, owing to greater convenience. As
the basis for afﬁrming HIV status, leading to linkage to care and
receipt of ART for those eligible, as well as prompting individ-
uals who learn they are HIV-positive to reduce the risks of on-
ward HIV transmission to others, the potential health gains
from self-testing are clear. What is more, self-testing may also
reduce costs, enabling savings in HIV testing programs that
can be reinvested in further expansion of testing or in delivery
of other HIV- and healthcare-related interventions.
Overall, under our base case assumptions, we estimate that
the introduction of self-testing will allow savings of around
$75 million over 20 years in Zimbabwe, with a low number of
DALYs averted (7000, in the context of an adult population of
7.5 million in mid-2013). If these assumptions hold in other set-
tings, self-testing should always be introduced, regardless of
how poorly or well resourced a health system is, because it
Figure 3. Cost-effective scenario under different assumptions of substitution and cost of self-testing (ST). Abbreviations: CET, cost-effectiveness thresh-
old; F, substitution of provider-delivered human immunodeﬁciency virus testing and counseling with self-testing during ﬁrst test; R, substitution of provider-
delivered human immunodeﬁciency virus testing and counseling with ST during repeat test.
Figure 4. Cost-effective scenario under different assumed increases in the rates of ﬁrst test and repeat test and cost of self-testing (ST). Abbreviation:
CET, cost-effectiveness threshold.
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leads to a win-win situation involving better health outcomes
at reduced cost. If we assume a CET of $500 (similar to
Zimbabwe’s gross domestic product per capita in 2012), the
$75 million savings could be used to avert at least 150 000
DALYs by introduction of interventions with incremental
cost-effectiveness ratios of $500 or less per DALY averted.
The monetary value of introducing self-testing to Zimbabwe
(ie, the net monetary beneﬁt, calculated as follows: [health
gains × CET] + cost savings [30]) would be $78.5 million over
20 years, indicating huge beneﬁts associated with supporting
the availability of self-testing in the country.
However, the population costs and health effects of self-testing
depend on a range of complex and interacting factors, and there
are plausible scenarios with characteristics such as an inadequate
cascade of care following self-testing that would result in worse
outcomes than those of the reference scenario.
Our sensitivity analyses provide insight into what determines
the magnitude of population health gains and suggest what pro-
grammatic recommendations may support optimal implemen-
tation of self-testing. First, the cost of self-testing relative to that
of PHTC appears to be the most important factor determining
cost-effectiveness, particularly at lower CETs. The OraQuick
HIV test kit designed for clinical use was sold for $4 in low-
income countries in 2005 [31]. Lower-cost alternatives to self-
testing would lead to additional gains if these were to become
available. The cost of distributing self-tests cannot be ignored,
but it is expected to be signiﬁcantly lower than the cost of pro-
viding PHTC. To the best of our knowledge, data on the cost of
rolling out self-testing are not currently available, and the only
study conducted in sub-Saharan Africa evaluating the uptake of
self-testing distributed the kit through community counselors
[8]. Second, we evaluated the impact of introducing self-testing
in addition to PHTC in a setting such as Zimbabwe, with a high
level of HIV diagnosis and ART coverage; in 2015, before the
introduction of self-testing, an estimated 85% of people with
HIV receive a diagnosis. It is likely that the impact of introduc-
ing self-testing would be even greater as the proportion of peo-
ple with HIV infection that is undiagnosed increases. Third, in
some circumstances, self-testing may lead to improved health
outcomes but also to higher costs, compared with the reference
scenario, if the overall level of testing (ie, the increase in the rate
of ﬁrst-time and repeat testing) increases dramatically because
of the availability of self-testing. The few studies conducted so
far on uptake of self-testing have found it to be extremely ac-
ceptable [7–10]. Studies in Malawi, for example, have shown
that 76% of adults avail themselves of self-testing by 12 months
following its introduction [10]. In settings with higher CETs, the
potential for health improvement will usually outweigh higher
costs. Appropriate targeting of self-testing, for example, to pop-
ulations afﬂicted by a higher HIV prevalence or that are known
to be less likely to test for HIV, such as men in many countries,
is likely to be necessary in such situations. There is also a risk in
some circumstances that self-testing may lead to worse health
outcomes, such as at CETs of $5000 or more, if ART initiation
occurs at a CD4+ T-cell count of <350 cells/μL or if the linkage
to care following a diagnosis prompted by a positive self-test is
low. This suggests that, to be translated into health gains, self-
testing needs to be accompanied by proactive interventions to
support a continuum of care following diagnosis. A study in
Malawi [8] investigated one scheme that could provide comple-
mentary beneﬁts—offering ART initiation at home among peo-
ple who self-test—and found that this signiﬁcantly increased the
probability of initiating ART within 6 months. Finally, there is
always potential for unintended adverse consequences associat-
ed with any public health intervention, so countries should
closely monitor their experiences with introducing self-testing.
Linkage to care, promoting counseling services, and reporting
of test outcomes need to be strengthened in support of such
public health interventions.
In conclusion, our results suggest that the introduction of
self-testing may not only be cost-effective, but also may be
cost saving under the assumptions described in the base
case scenario. Under these assumptions, self-testing should be
made available even in settings where resource-constraints
are greatest. Notably, in some circumstances, it may be neces-
sary to target self-testing to individuals who have certain risk
factors.
Supplementary Data
Supplementary materials are available at The Journal of Infectious Diseases
online (http://jid.oxfordjournals.org). Supplementary materials consist of
data provided by the author that are published to beneﬁt the reader. The
posted materials are not copyedited. The contents of all supplementary
data are the sole responsibility of the authors. Questions or messages regard-
ing errors should be addressed to the author.
Notes
Acknowledgments. We thank the University College London Legion
High Performance Computing Facility (Legion@UCL) and associated sup-
port services, for assistance in the completion of this work; and Cheryl John-
son, Stefano Bertozzi, Michael Borowitz, Charlene Brown, Augustine
Choko, Liz Corbett, Cari Courtenay-Quirk, Frances Cowan, Geoff Garnett,
Hendy Maheswaran, Jennifer Osborne, Christine Rousseau, and Mickey
Urdea, for insightful comments on the analysis plan and preliminary results
and useful discussion on this topic.
Disclaimer. The views expressed are not necessarily those of the UK
Department for International Development.
Financial support. This work was supported by the Bill and Melinda
Gates Foundation (global health grant OPP1064862) and the UK Depart-
ment for International Development (via the Lablite Project, to D. F. and
P. R.).
Potential conﬂicts of interest. A. P. has received research funds from
Bristol Myers Squibb and the World Health Organization and has received
payment for consulting work from Gilead Sciences and GSK Biologicals. All
other authors report no potential conﬂicts.
All authors have submitted the ICMJE Form for Disclosure of Potential
Conﬂicts of Interest. Conﬂicts that the editors consider relevant to the
content of the manuscript have been disclosed.
576 • JID 2015:212 (15 August) • Cambiano et al
References
1. Staveteig S, Wang S, Head SK, Bradley SEK, Nybro E. Demographic pat-
terns of HIV testing uptake in Sub-Saharan Africa. DHS Comparative
Reports 30. Calverton, MD: ICF International, 2013.
2. WHO/UNAIDS. Guidance on provider-initiated HIV testing and coun-
selling in health facilities. Geneva: World Health Organization, 2007.
http://whqlibdoc.who.int/publications/2007/9789241595568_eng.pdf.
Accessed 12 October 2013.
3. Report on the ﬁrst international symposium on self-testing for HIV: the
legal, ethical, gender, human rights and public health implications
of HIV self-testing scale-up. Geneva: World Health Organization, 2013.
4. Napierala Mavedzenge S, Baggaley R, Corbett EL. A review of self-test-
ing for HIV: research and policy priorities in a new era of HIV preven-
tion. Clin Infect Dis 2013; 57:126–38.
5. Pant Pai N, Sharma J, Shivkumar S, et al. Supervised and unsupervised
self-testing for HIV in high- and low-risk populations: a systematic
review. PLoS Med 2013; 10:e1001414.
6. Choko AT, Desmond N, Webb EL, et al. The uptake and accuracy of
oral kits for HIV self-testing in high HIV prevalence setting: a cross-
sectional feasibility study in Blantyre, Malawi. PLoS Med 2011; 8:
e1001102.
7. Corbett EL. Uptake, accuracy and linkage into care following access to
community-based self-testing for HIV in Malawi. Presented at: The
legal, ethical, gender, human rights and public health implications of
self-testing scale-up, Geneva, Switzerland, 8–9 April 2013.
8. MacPherson P, Lalloo D, Choko A, et al. Home assessment and initia-
tion of ART following HIV self-testing: a cluster-randomised trial to
improve linkage to ART in Blantyre, Malawi. 2013.
9. Kalibala S, Tun W, Muraah W, Cherutich P, Oweya E, Oluoch P.
Knowing myself ﬁrst’: feasibility of self-testing among health workers
in Kenya. Nairobi, Kenya: Population Council, 2011. http://www.
popcouncil.org/pdfs/2011HIV_KenyaHWSelfTesting.pdf. Accessed 5
April 2013.
10. Choko AT, MacPherson P, Webb EL, et al. One year outcomes following
community-based HIV self-testing: a prospective study in Malawi.
Presented at: 21st Conference on Retroviruses and Opportunistic Infec-
tions, Boston, Massachusetts, 3–6 March 2014.
11. Cambiano V, Bertagnolio S, Jordan MR, Lundgren JD, Phillips A.
Transmission of drug resistant HIV and its potential impact on mortal-
ity and treatment outcomes in resource-limited settings. J Infect Dis
2013; 207(suppl 2):S57–62.
12. Phillips AN, Pillay D, Miners AH, Bennett DE, Gilks CF, Lundgren JD.
Outcomes from monitoring of patients on antiretroviral therapy in
resource-limited settings with viral load, CD4 cell count, or clinical obser-
vation alone: a computer simulation model. Lancet 2008; 371:1443–51.
13. Phillips AN, Pillay D, Garnett G, et al. Effect on transmission of HIV-1
resistance of timing of implementation of viral load monitoring to
determine switches from ﬁrst to second-line antiretroviral regimens in
resource-limited settings. AIDS 2011; 25:843–50.
14. Phillips AN, Sabin C, Pillay D, Lundgren JD. HIV in the UK 1980–2006:
reconstruction using a model of HIV infection and the effect of antire-
troviral therapy. HIV Med 2007; 8:536–46.
15. Zimbabwe National Statistics Agency, MEASURE DHS, ICF Macro.
Zimbabwe Demographic and Health Survey 2010–11: preliminary
report. Harare, Zimbabwe: Zimbabwe national Statistics Agency, 2011.
16. US Food and Drug administration. First rapid home-use HIV kit
approved for self-testing, 2012. http://www.fda.gov/ForConsumers/
ConsumerUpdates/ucm310545.htm. Accessed 5 March 2013.
17. Asiimwe S, Oloya J, Song X, Whalen CC. Accuracy of un-supervised
versus provider-supervised self-administered HIV testing in Uganda:
a randomized implementation trial. AIDS Behav 2014; 18:2477–84.
18. Gaydos CA, Hsieh YH, Harvey L, et al. Will patients "opt in" to perform
their own rapid HIV test in the emergency department? Ann Emerg
Med 2011; 58(1 suppl 1):S74–8.
19. Pant Pai N, Behlim T, Abrahams L, et al. Will an unsupervised
self-testing strategy for HIV work in health care workers of South
Africa? A cross sectional pilot feasibility study. PLoS One 2013; 8:
e79772.
20. Jaspard M, Le MG, Saberan-Roncato M, et al. Finger-stick whole blood
HIV-1/-2 home-use tests are more sensitive than oral ﬂuid-based
in-home HIV tests. PLoS One 2014; 9:e101148.
21. Pant Pai N, Balram B, Shivkumar S, et al. Head-to-head comparison of
accuracy of a rapid point-of-care HIV test with oral versus whole-blood
specimens: a systematic review and meta-analysis. Lancet Infect Dis
2012; 12:373–80.
22. Rosen S, Fox MP. Retention in HIV care between testing and
treatment in sub-Saharan Africa: a systematic review. PLoS Med
2011; 8:e1001056.
23. Fonner VA, Denison J, Kennedy CE, O’Reilly K, Sweat M. Voluntary
counseling and testing (VCT) for changing HIV-related risk behavior
in developing countries. Cochrane Database Syst Rev 2012; 9:
CD001224.
24. National Medicine and Therapeutics Policy Advisory Committee
(NMTPAC) and The AIDS and TB Directorate Ministry of Health
and Child Care, Zimbabwe. Guidelines for antiretroviral therapy for
the prevention and treatment of HIV in Zimbabwe. Harare, Zimbabwe:
NMTPAC, 2013.
25. World Health Organization (WHO). Consolidated guidelines on the
use of antiretroviral drugs for treating and preventing HIV infection.
Geneva: WHO, 2013. http://www.who.int/hiv/pub/guidelines/arv2013/
en/index.html. Accessed 15 July 2013.
26. Edejer T-T, Baltussen R, Hutubessy HR, Acharya A, Evans DB, Murray
CJL. Making choices in health: WHO guide to cost effectiveness analy-
sis. Geneva: World Health Organization, 2003. http://www.who.int/
choice/publications/p_2003_generalised_cea.pdf. Accessed 15 October
2013.
27. Eaton JW, Menzies NA, Stover J, et al. Health beneﬁts, costs, and cost-
effectiveness of earlier eligibility for adult antiretroviral therapy and
expanded treatment coverage: a combined analysis of 12 mathematical
models. Lancet Global Health 2014; 2:e23–34.
28. Salomon JA, Vos T, Hogan DR, et al. Common values in assessing
health outcomes from disease and injury: disability weights measure-
ment study for the Global Burden of Disease Study 2010. Lancet
2012; 380:2129–43.
29. World Health Organization (WHO). WHO case deﬁnitions of HIV for
surveillance and revised clinical staging and immunological classiﬁca-
tion of HIV-related disease in adults and children. Geneva: WHO,
2007. http://www.who.int/hiv/pub/guidelines/HIVstaging150307.pdf.
Accessed 8 July 2013.
30. Drummond MF, Sculpher MJ, Torrance GW, O’Brien BJ, Stoddart GL.
Methods for the economic evaluation of health care programmes.
Oxford, United Kingdom: Oxford University Press, 2005.
31. UNICEF, United Nations Programme on HIV/AIDS, WHO, MSF.
Sources and prices of selected medicines and diagnostics for people
living with HIV/AIDS. 76th ed. Geneva: WHO, 2005. http://www.
unaids.org/en/media/unaids/contentassets/dataimport/publications/irc-
pub02/jc645-sources_prices_en.pdf. Accessed 25 October 2013.
Cost-effectiveness of HIV Self-Testing • JID 2015:212 (15 August) • 577
